Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

ABPI: Nothing to stop pharma using social media

denied it was a reaction to the Allergan Botox tweet case.

Allergan Botox tweet breaches UK pharma's Code of Practice

The Prescription Medicines Code of Practice Authority (PMCPA) ruled Allergan breached the Code on several counts after an employee accidentally tweeted publicly about Botox. ... Best known as a cosmetic anti-wrinkle treatment, Botox is also indicated for

Relieving the headache

Client:Allergan. Agency:Chandler Chicco Agency. Campaign:Launch of Botox for Chronic Migraine. Timescale:July 2010. ... burden of chronic migraine, the unmet patient need and the impending availability of BOTOX.

FDA approves Botox for incontinence

Botox was approved for its new indication following two clinical studies involving 691 patients with SCI or MS. ... Both studies demonstrated significant decreases in the frequency of incontinence episodes in the Botox group compared with placebo.

Positive opinion for Allergan's NDO treatment

A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... Allergan's BOTOX has received a positive opinion from the Irish Medicines Board, for the use of BOTOX for the management of

[ Previous 5 results ] 11 12 13 14 15 16 17 18 19 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...